TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Average Price Target of $63.00

TG Therapeutics, Inc. (NASDAQ:TGTX) has been given an average recommendation of “Moderate Buy” by the nine brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $63.00.

Several analysts have weighed in on TGTX shares. JPMorgan Chase & Co. boosted their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings raised TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Bank of America raised their price objective on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, September 1st.

TG Therapeutics Price Performance

NASDAQ:TGTX opened at $53.20 on Thursday. The firm has a market capitalization of $8.14 billion, a price-to-earnings ratio of 19.42, a P/E/G ratio of 2.30 and a beta of 1.80. TG Therapeutics has a 52-week low of $26.76 and a 52-week high of $59.30. The stock has a fifty day moving average of $54.52 and a 200 day moving average of $48.66. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. The company had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. During the same period in the previous year, the company earned $0.17 EPS. TG Therapeutics’s quarterly revenue was up 70.2% on a year-over-year basis. On average, research analysts expect that TG Therapeutics will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the sale, the director owned 168,640 shares in the company, valued at approximately $9,268,454.40. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 8.87% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Hedge funds have recently made changes to their positions in the business. Crossmark Global Holdings Inc. lifted its stake in shares of TG Therapeutics by 9.3% in the third quarter. Crossmark Global Holdings Inc. now owns 9,114 shares of the biopharmaceutical company’s stock worth $508,000 after buying an additional 772 shares in the last quarter. Stronghold Wealth Management L.L.C. increased its position in shares of TG Therapeutics by 6.3% during the third quarter. Stronghold Wealth Management L.L.C. now owns 3,922 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 231 shares in the last quarter. Chiron Capital Management LLC increased its position in shares of TG Therapeutics by 10.5% during the third quarter. Chiron Capital Management LLC now owns 4,200 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 400 shares in the last quarter. GAMMA Investing LLC increased its position in shares of TG Therapeutics by 15.4% during the third quarter. GAMMA Investing LLC now owns 5,929 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 789 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in TG Therapeutics by 45.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 312 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.